Does This Message From Moderna Mean Bad News for Novavax?
(NASDAQ: MRNA) recently gave an update on its pipeline and future goals, and the biotech had a lot to say. Today, everyone knows the company for its blockbuster COVID-19 vaccine -- it's only product. But in the coming five years, Moderna aims to launch as many as 15 new products across indication areas.
This doesn't mean Moderna is forgetting about the coronavirus vaccine though. In fact, this market giant announced something that could impact smaller rival Novavax (NASDAQ: NVAX). Both companies are vying for a share of the post-pandemic vaccine market, and both of them are working on a type of product that could wow the crowd. Let's take a look at the latest message from Moderna and whether it means bad news for Novavax.
First, a bit of background. Novavax and Moderna both were early leaders in coronavirus vaccine development, but Novavax fell behind, and its product entered the market a year later than Moderna's. As a result, Novavax missed out on the biggest revenue opportunity.
Source Fool.com
Moderna Inc. Aktie
Und Moderna Inc. steht derzeit mit 21 Buy-Einschätzungen und 2 Sell-Einschätzungen bei unserer Community gut im Kurs.
Eine deutliche Steigerung um mehr als 50% ist für Moderna Inc. mit einem Kursziel von 129 € gegenüber 80.88 € zu erwarten.
